VERO Biotech’s Post

Spotlight on BIO-Europe: We spoke to Elisabeth Lackner, member of the supervisory board of Marinomed Biotech AG, who talked about their partnering strategy. With an antiviral #Carragelose business, Marinosolv assets in Phase 3 and 2 for immunological indications, and their Solv4U platform that supports partners with solubilization of their product candidates, Marinomed certainly had a busy BIO-Europe. Watch the video below or directly on our YouTube channel where you can also find more highlights of the conference 👉 : https://bit.ly/477gOeI #bioeurope #bioeurope2023 #BiotechInvestment #HealthcareInnovation

Discovery chemists, ever dream of traveling from “data in” to “data out” along a path that includes entity registration? A DMTA workflow that saves you time and protects your investment? We've built the road. Meet some of its trailblazers on our July 31st webinar, including Steve Unger, Department Head and Director of Informatics at Pliant Therapeutics. Register for *Catalyzing DMTA Information into Insights* at https://lnkd.in/eBwDuFSw #medicinalchemistry #dmta #cheminformatics #drugdiscovery

Optimapharm will be attending #BIOSPAIN next week. We are looking for #biotech and #pharma companies working in the field of #clinicalresearch in order to support you with your phase I-IV #clinicaltrials management. 📩 sara.babic@optimapharm.eu #congress #Barcelona #Spain #clinicaldevelopment #ASEBIO #oncology #neurology #cardiology #patients #medicine #investigators #clinicaltrial #endocrinology #ophthalmology #infectiousdiseases #rarediseases #immunology #hematology #womenhealth #fertility #urology #rheumatology #hospitals

Cybin has an exciting journey ahead with multiple key data readouts and clinical milestones expected in the coming months and next year across the pipeline. We look forward to sharing: - Complete Phase 2 CYB003 efficacy and safety data in MDD in Q4 2023 - Phase 1 data for deuterated DMT molecules, CYB004 and SPL028, in Q4 2023 -Additional Phase 2 data assessing 12-week durability for CYB003 in Q1 2024 Cybin CEO Doug Drysdale said, “Looking ahead, Cybin plans to run four clinical studies in 2024, reflecting the team’s strong execution on strategic priorities and commitment to accelerating our programs. We are in an exciting period of clinical development, and we look forward to sharing important data readouts across our pipeline of differentiated therapeutics." Learn more: https://lnkd.in/gk5AXa4u #ChangingMinds #researchanddevelopment #cybin #psychedelicresearch #clinicalresearch #mentalhealthresearch #CybinInc #DrugDevelopment #Biotech #MentalHealth

Today marks the first day of trading in Trill Impact’s portfolio company Cinclus Pharma on Nasdaq Stockholm. The listing is an important milestone that enables continued development of the company’s drug candidate linaprazan glurate, which aims to improve the medical outcomes for patients suffering from severe stomach acid-related disorders worldwide.   Nina Rawal, Partner at Trill Impact Advisory and Co-head of Trill Impact Ventures was present when the opening bell rang this morning.   “It is of course very exciting to see Cinclus Pharma being listed on Nasdaq Stockholm today. To us, the fact that Cinclus Pharma has attracted investor interest in the current financial climate, is a great testament to the quality of the asset and the strong management team. When Trill Impact invested in Cinclus Pharma a couple of years back, we were confident that the company had the potential to become a global leader in the treatment of severe gastric acid-related disease. Since then, the company has reported strong Phase II data and is now ready to move into the final stage of clinical development". Read more about the #IPO here: https://lnkd.in/d7tvcBPC #impactinvesting #biotech #healthcare #lifescience #SDG3

#SwissBiotechDay #AkcesoAdvisors #AndrásIncze Join us at the Swiss Biotech Day next Monday and Tuesday, where our Founder & CEO, Andras Incze, will be serving as a jury member on two pitching sessions! 🎉   The Swiss Biotech Day, hosted by the Swiss Biotech Association, is one of Europe's premier biotechnology conferences, bringing together 2,000 professionals from the global life sciences community.   We are very much looking forward to explore how we at Akceso Advisors could help participating biotechs make sure they maximize the value of their asset. This, by helping them reaching target price for the target patient population, thus maximizing net revenue in an ever-more-challenging pharma landscape.   See you there! ✍ Find the registration link in the first comment.  

Thoughts on this? >> Illumina competitor Element Biosciences raises $277M in Series D >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #pharma #healthcare #pharmaceutical #productmarketing

🚀 $94m Series A!! The ADC field continues to soar. 🌟 It's no secret that Antibody-Drug Conjugates (ADCs) have been igniting the biopharma industry with their groundbreaking potential. Recent quarters witnessed Lilly making strategic moves, clinching two acquisitions in the ADC domain. Moreover, Bristol Myers Squibb's noteworthy $100 million upfront investment last year to acquire a Phase I-cleared ADC, sharing similarities with Firefly’s approach, underscores the immense promise of this therapeutic frontier. However, what truly makes this Series A funding remarkable is the innovative integration of degraders into ADCs, signaling a nascent yet profoundly transformative approach. Congratulations to Firefly Bio for this milestone achievement, and here's to the journey of pioneering advancements in healthcare! 🌐💡 #ADC #Biopharma #Innovation #SeriesA #HealthcareInvestment

A great example of how #KerusCloud benefits clinical trial design.. if you want to know more get in touch with the team and book a demo.

I am thrilled to announce the article for introducing Vacino Biotech published in current issue of Newsweek magazine. If you are interested in learning more about Vacino Biotech, you may visit the website of Vacino Biotech (https://vacinobiotech.com) or check out the current issue of Newsweek June 28 issue for more (https://www.newsweek.com/). #VacinoBiotech #OralCOVIDVaccine #miRNA #AlzheimersDisease #BrainDelivery #CNSDelivery #Newsweek